[1] Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin Disease:coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology, 2004, 232(3):823-829.
[2] Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 2003, 101(10):3875-3876.
[3] Spaepen K, Stroobants S, Dupont P, et al.[(18)F]FDG PET monitoring of tumour response to chemotherapy:does[(18)F]FDG uptake correlate with the viable tumour cell fraction?. Eur J Nucl Med Mol Imaging, 2003, 30(5):682-688.
[4] Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglueose in sareoidosis. J Nuel Med, 1994, 35(10):1647-1649.
[5] Tomas MB, Tronco GG, Karayalcin G, et al. FDG uptake in infectious mononucleosis. Clin Positron Imaging, 2000, 3(4):176.
[6] Kaste SC, Howard SC, McCarville EB, et al. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol, 2005, 35(2):141-154.
[7] Hong SP, Hahn JS, Lee JD, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan. Yonsei Med J, 2003, 44(5):779-786.
[8] Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med, 2004, 34(3):166-179.
[9] Kumar R, Maillard I, Schuster SJ, et al. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am, 2004, 42(6):1083-1100.
[10] Tatsumi M, Cohade C, Nakamoto Y, et al. Direct comparison of FDG PET and CT findings in patients with lymphoma:initial experience. Radiology, 2005, 237(3):1038-1045.
[11] Fuster D, Chiang S, Andreadis C, et al. Can[18F]fluorodeoxyglu-cose positron emission tomography imaging complement biopsy re-sults from the iliac crest for the detection of bone marrow involve-ment in patients with malignant lymphoma?. Nuel Med Commun, 2006, 27(1):11-15.
[12] Delbeke D, Martin WH, Morgan DS, et al. 2-deoxy-2-[F-18] fluoro-Dglucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol, 2002, 4(1):105-114.
[13] Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bieenter trial. Cancer, 2001,91(5):889-899.
[14] Schoder H, Meta J, Yap C, et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 200142(8):1139-1143.
[15] Lowe VJ, Wiseman GA. Assessment of lymphoma therapy using (18) F-FDG PET. J Nuel Med, 2002, 43(8):1028-1030.
[16] Yamane T, Daimaru O, ho S, et al. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. J Nucl Med, 2004, 45(11):1838-1842.
[17] Castellucci P, Zinzani P, Nanni C, et al.18F-FDG PET early arier radiotherapy in lymphoma patients. Cancer Biother Radiopharm, 2004, 19(5):606-612.
[18] Lavely WC, Delbeke D, Greer JP, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys, 2003, 57(2):307-315.
[19] Jerusalem G, Hustinx R, Beguin Y, et al. Positron emission tomography imaging for lymphoma. Curr Opin Oncol, 2005, 17(5):441-445.